Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 51 - 60 of 133

Selected Filters:
13 December 2023

Value Chain Situation Analyses

Situation analyses are an initial step in supporting national planning for the introduction and scale-up of PrEP methods. These tools can be used by policymakers or others supporting policy development for new PrEP methods (e.g., nongovernmental organizations, donors) to conduct an analysis to assess the existing situation for the introduction of the new product. Value…

Normative Guidance/Policies, Research

4 December 2023

The Lancet HIV- Special Issue on PrEP

The December 2023 issue of The Lancet HIV contains numerous articles featuring the latest research and commentaries on PrEP, including oral PrEP, injectable CAB for PrEP, the dapirivine vaginal ring, and PEP.

Research

External Link
30 November 2023

What can modelling tell us about the scale-up of CAB for PrEP?

This factsheet summarises the results of mathematical modelling exercises of Cabotegravir (CAB) for PrEP rollout undertaken by researchers affiliated with the HIV Modelling Consortium. These results can help implementers and policymakers understand what to expect and guide early policy decisions to ensure CAB for PrEP is able to have maximum impact on reducing the HIV…

Research, Service Delivery, Testing

Document
15 November 2023

Quality Improvement Brief

The Quality Improvement Collaborative (QIC) is a component of the CATALYST study that refines and makes context-specific improvements to the enhanced service delivery package to make it scalable for delivering PrEP choice. The QIC’s multi-country design enables rich learning and problem-solving by providing QI faculty, advisors, coaches, and teams from all CATALYST countries opportunities to…

Monitoring & Evaluation

Document
15 November 2023

Insights Report: Communicating the PrEP Category to AGYW

PrEP Category Positioning Market Research Validation Insights from Kenya, South Africa, and Zimbabwe This report is a comprehensive look at what was learned through validating the positioning direction. It explains the methodology, outlines country-specific reactions to the positioning direction, and distills key findings that were leveraged to adjust and refine the positioning to honor the…

Research

Document
15 November 2023

Communicating the PrEP Category to Adolescent Girls and Young Women

This strategy brief is intended for use by implementers working to generate demand for PrEP among AGYW. Drawing on all learnings throughout the positioning process, the brief provides a narrative explanation of how to communicate the PrEP category to AGYW and includes actionable guidance on how best to develop communication that will get the attention…

Monitoring & Evaluation

Document
15 November 2023

Coordinating Implementation Science for CAB for PrEP: Linking Modellers with the Latest Implementation Science Evidence, September 2023

This document summarises key takeaways from a September 2023 BioPIC Think Tank to align modellers and implementation science researchers on data and evidence needs to address cabotegravir for PrEP evidence gaps.

Research

Document
14 November 2023

Efficacy and Safety of Long-Acting Cabotegravir Compared with Daily Oral Tenofovir Disoproxil Fumarate Plus Emtricitabine to Prevent HIV Infection in Cisgender Men and Transgender Women who Have Sex with Men 1 Year after Study Unblinding: A secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial

This article from The Lancet HIV describes findings from the first unblinded year of the HIV Prevention Trials Network (HPTN) 083 study, which compared safety and efficacy of cabotegravir and tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) as HIV prevention for transgender women and men who have sex with men in Argentina, Brazil, Peru, South Africa, Thailand, the…

Research

External Link
13 October 2023

Coordinating Implementation Science for CAB for PrEP: Inclusion of Key Populations

This document summarises key takeaways from the BioPIC Think Tank focused on strategies to include trans and gender diverse people, gay and bisexual men who have sex with men, sex workers, and people who use and inject drugs in implementation science projects as well as the rollout and scale-up of cabotegravir for PrEP.

Research

Document
13 October 2023

Advocates’ Primer on Injectable Cabotegravir for PrEP

This document, designed for advocates, focuses on injectable cabotegravir for PrEP, outlining what’s known and what’s next for this emerging biomedical HIV prevention strategy. A summary slide deck with additional details can be found here.

Community/Advocacy

External Link